Stock data
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA) reported revenue of US$25.42M and net income of -US$143.75M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$25.42M | — | -US$157.90M | -US$143.75M | — |
| 2024 | US$210.78M | — | US$47.01M | US$65.63M | — |
| 2023 | US$129.01M | — | -US$3.16M | -US$6.68M | — |
| 2022 | — | — | -US$97.25M | -US$94.62M | — |
| 2021 | — | — | -US$51.13M | -US$51.16M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.90M | -US$42.76M | — |
| 2026-03-31 | US$0.88M | -US$39.72M | — |
| 2025-12-31 | US$1.30M | -US$39.16M | — |
| 2025-09-30 | US$1.61M | -US$44.13M | — |
| 2025-06-30 | US$1.95M | -US$43.10M | — |
| 2025-03-31 | US$20.56M | -US$17.35M | — |
| 2024-12-31 | US$37.40M | US$1.13M | — |
| 2024-09-30 | US$19.57M | -US$14.03M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.